ASCO 2024 | Treatment deintensification and immunotherapy in HPV16+ oropharyngeal cancer

Ari Rosenberg, MD, University of Chicago, Chicago, IL, discusses the potential for treatment deintensification and immunotherapy in HPV16-positive oropharyngeal cancer. Findings suggest that response-adaptive de-escalation and neoadjuvant HPV-specific immunotherapy can reduce long-term side effects and improve antitumor immunity. Ongoing Phase II trials aim to refine patient selection using circulating tumor HPV DNA clearance. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.